1173C>T polymorphism in VKORC1 modulates the required warfarin dose

被引:24
作者
Kosaki, K.
Yamaghishi, C.
Sato, R.
Semejima, H.
Fuijita, H.
Tamura, K.
Maeyama, K.
Yamagishi, H.
Sugaya, A.
Dodo, H.
Tanigawara, Y.
Takahashi, T.
机构
[1] Keio Univ, Sch Med, Dept Pediat, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Dept Pharm, Shinjuku Ku, Tokyo 1608582, Japan
[3] Tokyo Metropolitan Kiyose Childrens Hosp, Dept Cardiol, Tokyo 1398551, Japan
[4] Natl Ctr Child Hlth & Dev, Dept Cardiol, Setagaya Ku, Tokyo 2040024, Japan
关键词
warfarin; pharmacogenetics; polymorphism; vitamin K;
D O I
10.1007/s00246-005-1150-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The response to warfarin is highly variable among individuals and such variability is likely to have some genetic basis. We evaluted the effect of VKORC1 polymorphisms on warfarin response among Japanese, taking advantage of its unique population structure in which CYP2C9 *2 and *3 alleles are relatively rare. Thirty-one patients (12-34 years old; median, 22) on warfarin were recruited from a pediatric cardiology clinic. Genotyping of the C > T polymorphism at position 1173 in intron 1 of VKORC1 revealed that 26 patients (84%) were T/T homozygotes at nucleotide 1173, whereas 5 (16%) were C/T heterozygotes. Complete linkage disequilibrium was observed between the 1173C > T polymorphism and another polymorphism, the 3730G > A, in the 3' untranslated region. The C/T heterozyogtes at the 1173C > T polymorphism tended to require more warfarin than the T/T homozygotes, when adjusted for international normalized ratio (p = 0.003). Both the 1173C > T polymorphism and the 3730G > A polymorphism are likely to be inert from a functional standpoint. Rather, based on the complete linkage disequilibrium between 1173C > T and 3730G > A polymorphisms, we suspect that the actual change that defines the relative resistance to warfarin may be present in the proximity of these two polymorphisms.
引用
收藏
页码:685 / 688
页数:4
相关论文
共 15 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
*BRIT COMM STAND H, 1998, BRIT J HAEMATOL, V101, P34
[3]  
Chenhsu RY, 2000, ANN PHARMACOTHER, V34, P1395
[4]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[5]  
FINH SD, 1996, ANN INTERN MED, V124, P970
[6]   Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit I [J].
Harrington, DJ ;
Underwood, S ;
Morse, C ;
Shearer, MJ ;
Tuddenham, EGD ;
Mumford, AD .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) :23-26
[7]   FACTORS AFFECTING THE MAINTENANCE DOSE OF WARFARIN [J].
JAMES, AH ;
BRITT, RP ;
RASKINO, CL ;
THOMPSON, SG .
JOURNAL OF CLINICAL PATHOLOGY, 1992, 45 (08) :704-706
[8]   Pharmacogenetics and adverse drug reactions [J].
Meyer, UA .
LANCET, 2000, 356 (9242) :1667-1671
[9]   IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].
RETTIE, AE ;
WIENKERS, LC ;
GONZALEZ, FJ ;
TRAGER, WF ;
KORZEKWA, KR .
PHARMACOGENETICS, 1994, 4 (01) :39-42
[10]   Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 [J].
Rost, S ;
Fregin, A ;
Ivaskevicius, V ;
Conzelmann, E ;
Hörtnagel, K ;
Pelz, HJ ;
Lappegard, K ;
Seifried, E ;
Scharrer, I ;
Tuddenham, EGD ;
Müller, CR ;
Strom, TM ;
Oldenburg, J .
NATURE, 2004, 427 (6974) :537-541